New Amsterdam Pharma
Investors & Media
Medical Information
About Us
Company OverviewOur Leadership
Our Focus
Cardiovascular DiseaseUnmet Need in Cardiovascular DiseaseWhat is CETP?Other Lipid-Related Conditions
Science & Pipeline
Obicetrapib (TA-8995)Combination TherapyScientific PublicationsGrants
Patients & Caregivers
Why Cholesterol MattersPatient Advocacy & ResourcesClinical Trials & Expanded Access
Careers
Contact Us
menu
‍
NewAmsterdam Pharma
  • Home
  • About Us
    • Company Overview
    • Our Leadership
  • Our Focus
    • Cardiovascular Disease
    • Unmet Need in Cardiovascular Disease
    • What is CETP?
    • Other Lipid-Related Conditions
  • Science & Pipeline
    • Obicetrapib (TA-8995)
    • Combination Therapy
    • Scientific Publications
    • Grants
  • Patients & Caregivers
    • Why Cholesterol Matters
    • Patient Advocacy & Resources
    • Clinical Trials & Expanded Access
  • Careers
  • Contact Us
  • Investors & Media
  • Medical Information

Medical Resource Center

The following information is designed for healthcare professionals in the United States.

Please confirm you are a U.S. healthcare professional.
YES, I AM NO, I AM NOT
The content of this is intended only for US healthcare professionals licensed to practice in the United States. This resource is intended to provide balanced, scientific, and evidence-based information in response to physician request. Content may include information on investigational agents that have not been approved by the US Food and Drug Administration and may include content and statements beyond approved labeling for some products. These slides are not accredited continuing medical education.
MRCCME

All the available medical resources housed in one place, so you can quickly and easily access what you need. We are confident you will find the Medical Resource Center valuable and look forward to future feedback!

REQUEST AN MSL

Please use the filter to begin your search.

Clear selection
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
Last Modified:
2023-12-22
Publication
Review
Obicetrapib
View Publication
Tolerability, pharmacokinetics and pharmacodynamics of TA-8995
Tolerability, pharmacokinetics and pharmacodynamics of TA-8995
Last Modified:
2014-03-17
PK
Publication
Review
View Publication
Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents
Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents
Last Modified:
2021-11-20
Publication
Review
CETP Inhibition
View Publication
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
Last Modified:
2022-08-11
Publication
Trial
Obicetrapib
View Publication
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Last Modified:
2023-05-20
Publication
Trial
Obicetrapib
View Publication
The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease
The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease
Last Modified:
2023-10-28
Publication
Review
CETP Inhibition
View Publication
PRIVACY POLICYCookie Settings
About UsOUR FOCUSSCIENCE & PIPELINEPatients & CaregiversCAREERSCONTACT US
INVESTORS & MEDIAMedical information
INVESTORS & MEDIAFOR HEALTHCARE PROFESSIONALS
© 2024 NewAmsterdam Pharma